Cancer diagnostics company, Pacific Edge, has reported a 6.8% increase in tests processed at its laboratories in the fourth quarter of the 2025 financial year.
The rise in laboratory throughput was attributed to higher adoption rates in the US.
In the US, total laboratory throughput reached 6,490 tests, up 11.7% from the previous quarter.
This increase was driven by a greater number of unique US ordering clinicians and a higher number of tests ordered per clinician.
However, the company said its Asia Pacific total laboratory throughput declined by 15% to 1,087 tests.
For the entire financial year, total volumes were down 11.5% to 28,894 tests.
See more
